勘误：对“Sphingosine-1-phosphate, a novel TREM2 ligand, promotes microglial phagocytosis to protect against ischemic brain injury”[《中国药理学通报》12 (2022) 1885 - 1898]的作者更正。
Erratum: Author correction to "Sphingosine-1-phosphate, a novel TREM2 ligand, promotes microglial phagocytosis to protect against ischemic brain injury" [Acta Pharm Sin B 12 (2022) 1885-1898].
作者信息
Xue Tengfei, Ji Juan, Sun Yuqin, Huang Xinxin, Cai Zhenyu, Yang Jin, Guo Wei, Guo Ruobing, Cheng Hong, Sun Xiulan
机构信息
Department of Pharmacology, Neuroprotective Drug Discovery Key Laboratory, Jiangsu Key Laboratory of Neurodegeneration, Nanjing Medical University, Nanjing 211166, China.
The First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China.
出版信息
Acta Pharm Sin B. 2025 May;15(5):2813-2814. doi: 10.1016/j.apsb.2025.02.032. Epub 2025 Feb 25.
Abstract
[This corrects the article DOI: 10.1016/j.apsb.2021.10.012.].
摘要
[本文更正了文章的数字对象标识符：10.1016/j.apsb.2021.10.012。]
相似文献
1
Erratum: Author correction to "Sphingosine-1-phosphate, a novel TREM2 ligand, promotes microglial phagocytosis to protect against ischemic brain injury" [Acta Pharm Sin B 12 (2022) 1885-1898].勘误：对“Sphingosine-1-phosphate, a novel TREM2 ligand, promotes microglial phagocytosis to protect against ischemic brain injury”[《中国药理学通报》12 (2022) 1885 - 1898]的作者更正。
Acta Pharm Sin B. 2025 May;15(5):2813-2814. doi: 10.1016/j.apsb.2025.02.032. Epub 2025 Feb 25.
2
Erratum: Author correction to 'Pharmacologically targeting molecular motor promotes mitochondrial fission for anti-cancer' [Acta Pharm Sin B 11 (2021) 1853-1866].勘误：“Pharmacologically targeting molecular motor promotes mitochondrial fission for anti-cancer” [《中国药理学报B》11 (2021) 1853-1866]的作者更正。
Acta Pharm Sin B. 2024 May;14(5):2358. doi: 10.1016/j.apsb.2024.02.013. Epub 2024 Feb 21.
3
Erratum: Author correction to "PRMT6 promotes tumorigenicity and cisplatin response of lung cancer through triggering 6PGD/ENO1 mediated cell metabolism" [Acta Pharm Sin B 13 (2023) 157-173].勘误：“PRMT6通过触发6PGD/ENO1介导的细胞代谢促进肺癌的肿瘤发生和顺铂反应”一文的作者更正[《中国药理学报B》13 (2023) 157 - 173]。
Acta Pharm Sin B. 2025 Apr;15(4):2297-2299. doi: 10.1016/j.apsb.2025.02.006. Epub 2025 Feb 12.
4
Erratum: Author correction to "Generation of Gal-enhanced bifunctional tumor vaccine" [Acta Pharm Sin B 12 (2022) 3177-3186].勘误：“Gal增强型双功能肿瘤疫苗的生成”[《中国药理学通报》12 (2022) 3177 - 3186]的作者更正。
Acta Pharm Sin B. 2025 Feb;15(2):1207. doi: 10.1016/j.apsb.2024.11.021. Epub 2024 Nov 29.
5
Erratum: Author correction to 'FGF4 protects the liver from immune-mediated injury by activating CaMKK-PINK1 signal pathway to inhibit hepatocellular apoptosis' [Acta Pharm Sin B 14 (2024) 1605-1623].勘误：对“FGF4通过激活CaMKK-PINK1信号通路抑制肝细胞凋亡从而保护肝脏免受免疫介导损伤”一文的作者更正[《药学学报B》14 (2024) 1605-1623]。
Acta Pharm Sin B. 2024 Jun;14(6):2791-2793. doi: 10.1016/j.apsb.2024.04.008. Epub 2024 Apr 9.
6
Erratum: Author correction to "The neuroprotective effect of traditional Chinese medicinal plants-A critical review" [Acta Pharm Sin B 13 (2023) 3208-3237].勘误：《中药的神经保护作用——综述》[《药学学报B》13 (2023) 3208 - 3237]的作者更正。
Acta Pharm Sin B. 2025 Apr;15(4):2300. doi: 10.1016/j.apsb.2024.12.002. Epub 2024 Dec 3.
7
Erratum: Author correction to "SHP2 inhibition triggers anti-tumor immunity and synergizes with PD-1 blockade" [Acta Pharm Sin B 9 (2019) 304-315].勘误：“SHP2抑制引发抗肿瘤免疫并与PD-1阻断协同作用”[《中国药理学通报》9 (2019) 304 - 315]的作者更正。
Acta Pharm Sin B. 2025 May;15(5):2810-2812. doi: 10.1016/j.apsb.2024.12.023. Epub 2024 Dec 23.
8
Erratum: Author correction to "Gas-propelled nanomotors alleviate colitis through the regulation of intestinal immunoenvironment-hematopexis-microbiota circuits" [Acta Pharm Sin B 14 (2024) 2732-2747].勘误：《气体驱动纳米马达通过调节肠道免疫环境-血液结合素-微生物群回路缓解结肠炎》[《药学学报B》14 (2024) 2732-2747]的作者更正。
Acta Pharm Sin B. 2024 Sep;14(9):4193. doi: 10.1016/j.apsb.2024.06.005. Epub 2024 Jun 15.
9
Erratum: Author correction to 'Co-delivery of nigericin and decitabine using hexahistidine-metal nanocarriers for pyroptosis-induced immunotherapeutics' [Acta Pharm Sin B 12 (2022) 4458-4471].勘误：“使用六组氨酸金属纳米载体共递送尼日利亚菌素和地西他滨用于焦亡诱导的免疫治疗”[《中国药理学报B》12 (2022) 4458 - 4471]的作者更正。
Acta Pharm Sin B. 2024 May;14(5):2359-2360. doi: 10.1016/j.apsb.2024.02.021. Epub 2024 Feb 29.
10
Erratum: Author correction to "Identification of anthelmintic parbendazole as a therapeutic molecule for HNSCC through connectivity map-based drug repositioning" [Acta Pharm Sin B 12 (2022) 2429-2442].勘误：作者对“通过基于连接图谱的药物重新定位鉴定抗蠕虫药帕苯达唑作为头颈部鳞状细胞癌的治疗分子”[《中国药理学通报》12 (2022) 2429-2442]进行的更正。
Acta Pharm Sin B. 2024 Nov;14(11):5089-5090. doi: 10.1016/j.apsb.2024.09.006. Epub 2024 Sep 10.
Zotero 插件